LigoCyte’s Scientific Advisory Board members are internationally recognized researchers. Their collective expertise complements the focus of our product development efforts. Advisory Board member responsibilities include the critical review of our product development programs and advising management and the Board of Directors on our technical efforts.

Bryan Finkle, Ph.D., Director of Pharmacology (retired), Genentech, Inc.
Dr. Finkle is educated in chemistry, pharmacology and toxicology, and throughout his distinguished career he has been consultant to the FDA, NIDA, and the NFL. His consultation relates to toxicology, pharmacology, pharmaceutical drug development and clinical trials design.

Harry Greenberg, M.D., Joseph D. Grant Professor and Co-Chairman, Department of Medicine, Stanford University
Dr. Greenburg’s scientific focus is pathogenic viruses that infect the liver, GI tract and respiratory tract. He has focused extensively on the molecular mechanisms of pathogeneses, viral determinants of protective immunity, tissue tropism, vaccine development and epidemiology of various viruses, with a specific emphasis on rotavirus and influenza. A former Chairman of the CBER’s Vaccines and Related Biologic Products Advisory Committee, Dr. Greenberg also spent two years as Aviron’s, then MedImmune’s, Senior Vice President of Research and Chief Scientific Officer. His consultation relates to vaccine development, determinants of protective immunity, adjuvants, and vaccine delivery.

Jerry McGhee, Ph.D., Professor of Microbiology, University of Alabama, Birmingham
Dr. McGhee is one of the country’s foremost experts in mucosal immunology, specializing in mucosal immunity and vaccines, mucosal tolerance and inflammation of mucosal tissues. He is the former director of the Immunobiology Vaccine Center (IVC), whose mission is to foster vaccine research with an emphasis on mucosal vaccine development. His consultation relates to the regulation of mucosal immunity, inflammation, tolerance and vaccine development

George R. Siber, M.D., Executive Chairman, Genocea Biosciences and Professor of Medicine, Massachusetts Medical School
Dr. Siber is widely regarded as one of the leading global authorities in vaccines and was previously the Executive Vice President and Chief Scientific Officer of Wyeth Vaccines. While at Wyeth, Dr. Siber oversaw the development and approval of multiple widely-used childhood vaccines including an acellular pertussis vaccine (Acel-Imune), a meningococcal meningitis vaccine (Meningitec), and a pneumococcal vaccine (Prevnar). Prior to joining Wyeth, Dr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. During this time, Dr. Siber oversaw research and manufacturing of multiple vaccines and immune globulins including Respigam, a human immune globulin against RSV, which was the precursor of Synagis.

Marian Neutra, Ph.D., E. & M. Gordon Distinguished Professor of Pediatrics, Children’s Hospital Harvard University
Dr. Neutra is the director of the Gastrointestinal Cell Biology Research Laboratory at the Children’s Hospital. Her work focuses on interactions of pathogenic micro-organisms and antigens with the epithelial surfaces of mucosal tissues and with the mucosal immune system. Her consultation relates to LigoCyte’s mucosal vaccine franchise, infectious disease targets, mucosal immunity, adjuvants, and vaccine delivery.

Russ Middaugh, Ph.D., A. & T. Higuichi Distinguished Professor of Pharmaceutical Chemistry, University of Kansas
Dr. Middaugh’s major area of interest is vaccines, and is a former senior formulation scientist in the Vaccine Division and the Department of Human Genetics at Merck and Co. Prior to Merck, Dr. Middaugh was a visiting scientist at the Massachusetts Institute of Technology, Cambridge. His current work explores the structural aspects of protein delivery and use of adjuvants to enhance immunogenicity of vaccine formulations. His consultation relates to protein expression, stabilization of proteins, and protein folding for the formulation of therapeutic proteins and vaccines.

In addition to the SAB members listed above, LigoCyte retains key scientific consultants in the field who also participate in SAB meetings and reviews.